The Company intends to use the net proceeds of the offering to fund the STEADFAST Study (its ongoing Phase 3 trial of azeliragon, a drug candidate for the treatment of Alzheimer's disease), further clinical development of its other drug candidates (including two drug candidates for the treatment of type 2 diabetes that are in or commencing Phase 2 studies) and for working capital and other general corporate purposes.
The offering is being made only by means of a prospectus. A copy of the
final prospectus related to the offering may be obtained, when
available, from
A registration statement relating to these securities has been filed
with, and declared effective by, the
About vTv Therapeutics
vTv
Forward-Looking Statements
This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements include information concerning the Company's possible or assumed future results of operations, including descriptions of the Company's business strategy. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that the Company has made in light of its experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Although the Company believes that these forward-looking statements are based on reasonable assumptions, we can give no assurance they will prove to be correct. Therefore, you should be aware that many factors could affect the Company's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors are discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and elsewhere in the Company's registration statement.
You should keep in mind that any forward-looking statement made by the Company herein, or elsewhere, speaks only as of the date on which made. New risks and uncertainties come up from time to time, and it is impossible for the Company to predict these events or how they may affect it. The Company has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150729006885/en/
Source: vTv
Investors
The Trout Group
Marc Panoff, 646-378-2958
mpanoff@troutgroup.com
or
Media
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com